New perspectives in cancer immunotherapy: targeting IL-6 cytokine family
Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/11/11/e007530.full |
| _version_ | 1797426649020497920 |
|---|---|
| author | Maria Florencia Soler Andrea Abaurrea Peio Azcoaga Angela M Araujo Maria M Caffarel |
| author_facet | Maria Florencia Soler Andrea Abaurrea Peio Azcoaga Angela M Araujo Maria M Caffarel |
| author_sort | Maria Florencia Soler |
| collection | DOAJ |
| description | Chronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment.The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed. |
| first_indexed | 2024-03-09T08:33:23Z |
| format | Article |
| id | doaj.art-ee77663748f54092be0a43ef363ec5ab |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-09T08:33:23Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-ee77663748f54092be0a43ef363ec5ab2023-12-02T19:15:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-01111110.1136/jitc-2023-007530New perspectives in cancer immunotherapy: targeting IL-6 cytokine familyMaria Florencia Soler0Andrea Abaurrea1Peio Azcoaga2Angela M Araujo3Maria M Caffarel4Biogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, SpainBiogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, SpainBiogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, SpainBiogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, SpainBiogipuzkoa (previously known as Biodonostia) Health Research Institute, Donostia-San Sebastian, SpainChronic inflammation has been recognized as a canonical cancer hallmark. It is orchestrated by cytokines, which are master regulators of the tumor microenvironment (TME) as they represent the main communication bridge between cancer cells, the tumor stroma, and the immune system. Interleukin (IL)-6 represents a keystone cytokine in the link between inflammation and cancer. Many cytokines from the IL-6 family, which includes IL-6, oncostatin M, leukemia inhibitory factor, IL-11, IL-27, IL-31, ciliary neurotrophic factor, cardiotrophin 1, and cardiotrophin-like cytokine factor 1, have been shown to elicit tumor-promoting roles by modulating the TME, making them attractive therapeutic targets for cancer treatment.The development of immune checkpoint blockade (ICB) immunotherapies has radically changed the outcome of some cancers including melanoma, lung, and renal, although not without hurdles. However, ICB shows limited efficacy in other solid tumors. Recent reports support that chronic inflammation and IL-6 cytokine signaling are involved in resistance to immunotherapy. This review summarizes the available preclinical and clinical data regarding the implication of IL-6-related cytokines in regulating the immune TME and the response to ICB. Moreover, the potential clinical benefit of combining ICB with therapies targeting IL-6 cytokine members for cancer treatment is discussed.https://jitc.bmj.com/content/11/11/e007530.full |
| spellingShingle | Maria Florencia Soler Andrea Abaurrea Peio Azcoaga Angela M Araujo Maria M Caffarel New perspectives in cancer immunotherapy: targeting IL-6 cytokine family Journal for ImmunoTherapy of Cancer |
| title | New perspectives in cancer immunotherapy: targeting IL-6 cytokine family |
| title_full | New perspectives in cancer immunotherapy: targeting IL-6 cytokine family |
| title_fullStr | New perspectives in cancer immunotherapy: targeting IL-6 cytokine family |
| title_full_unstemmed | New perspectives in cancer immunotherapy: targeting IL-6 cytokine family |
| title_short | New perspectives in cancer immunotherapy: targeting IL-6 cytokine family |
| title_sort | new perspectives in cancer immunotherapy targeting il 6 cytokine family |
| url | https://jitc.bmj.com/content/11/11/e007530.full |
| work_keys_str_mv | AT mariaflorenciasoler newperspectivesincancerimmunotherapytargetingil6cytokinefamily AT andreaabaurrea newperspectivesincancerimmunotherapytargetingil6cytokinefamily AT peioazcoaga newperspectivesincancerimmunotherapytargetingil6cytokinefamily AT angelamaraujo newperspectivesincancerimmunotherapytargetingil6cytokinefamily AT mariamcaffarel newperspectivesincancerimmunotherapytargetingil6cytokinefamily |